Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,494.14 -7.51 -0.05%
S&P 500 1,878.34 2.95 0.16%
NASDAQ 4,137.82 10.85 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,171.08 -4.89 -0.15%
FTSE 100 6,684.33 9.59 0.14%
DAX 9,483.95 -60.24 -0.63%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research



     Financial Results, Conference Presentation Schedule, Clinical Trial
  Initiation, Recognition, and Dividend Payment - Research Report on Cantel,
                Chimerix, Verastem, Amedisys, and Ensign Group

PR Newswire

NEW YORK, December 25, 2013

NEW YORK, December 25, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Cantel
Medical Corp. (NYSE: CMN), Chimerix, Inc. (NASDAQ: CMRX), Verastem, Inc.
(NASDAQ: VSTM), Amedisys, Inc. (NASDAQ: AMED), and The Ensign Group, Inc.
(NASDAQ: ENSG). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Cantel Medical Corp. Research Report

On December 5, 2013, Cantel Medical Corp. (Cantel) reported financial results
for Q1 FY 2014 (period ended October 31, 2013). In Q1 FY 2014, the Company's
net income was $11.2 million, or $0.27 per diluted share, on sales of $118.3
million, compared with Q1 FY 2013 net income of $9.6 million, or $0.23 per
diluted share, on sales of $99.7 million. "We are pleased to have delivered
record sales and earnings this quarter. We achieved good financial performance
in all three major business segments - Endoscopy, Water Purification and
Filtration, and Healthcare Disposables. All three business units have greatly
benefitted from further investments in new product development, sales and
marketing programs, and the integration of recent acquisitions. Most
importantly, for the second consecutive quarter we had strong organic sales
growth of 10%. Further, our total sales growth of 19% demonstrates the success
of our acquisition program," said Andrew Krakauer, President and CEO of
Cantel. The Full Research Report on Cantel Medical Corp. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/cda3_CMN

--

Chimerix, Inc. Research Report

On December 19, 2013, Chimerix, Inc. (Chimerix) announced its participation at
the 32^nd Annual J.P. Morgan Healthcare Conference. According to Chimerix,
thej Company's President and CEO, Kenneth I. Moch, is scheduled to present on
Thursday, January 16, 2014 at 12:30 p.m. PST / 3:30 p.m. ES, at the Westin St.
Francis Hotel in San Francisco. The Company informed that a live audio webcast
of the presentation will be available on the Investor Relations section of its
website. The Full Research Report on Chimerix, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/2797_CMRX

--

Verastem, Inc. Research Report

On December 10, 2013, Verastem, Inc. (Verastem) announced the initiation of a
Phase 1 trial of VS-5584, a dual mTORC1/2 and PI3K inhibitor, in patients with
advanced solid tumors or lymphoma. "We are conducting this study with clinical
investigators who have extensive experience with PI3K and mTOR inhibitors and
applying our expertise in cancer stem cell biology to progress the development
of the compound," said Dr. Joanna Horobin, Chief Medical Officer of Verastem.
The Company stated that it presented preclinical research on the ability of
VS-5584 to preferentially target cancer stem cells at the American Association
of Cancer Research and the AACR-NCI-EORTC Molecular Targets Meetings in 2013.
According to the Company, the study data demonstrated that VS-5584 has
equipotency against all four human Class I PI3K isoforms and both the mTORC1
and mTORC2 complexes of the mTOR kinase. According to Verastem, the study data
also showed that VS-5584 decreased cancer stem cells across multiple in vitro
and in vivo cancer models, in contrast to the effect of standard care
treatments like chemotherapy. The Full Research Report on Verastem, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cbd0_VSTM

--

Amedisys, Inc, Research Report

On December 18, 2013, Amedisys, Inc. (Amedisys) announced that 155 of its care
centers across the country have been named to the 2013 HomeCare Elite, a
compilation of the top-performing home health agencies in the US, compiled
annually by OCS Home Care and DecisionHealth."The 2013 HomeCare Elite winners
demonstrate a commitment to providing patient-centered care and serving as
leaders in the home health community. Their success is a tribute that managing
healthcare data and utilizing it for improvement initiatives lead to high
quality care, and we recognize them for their outstanding achievements," said
Mary Oakes, Senior Vice President of Post-Acute at National Research. Oakes
added, "We congratulate Amedisys on being recognized as a top home care
agency." Kate Jones, RN, Chief Clinical Officer of Amedisys, said, "Making the
2013 HomeCare Elite list is an honor that recognizes our exceptional care
teams and their commitment to meeting the greatest needs of our patients in
the comfort of their own homes." The Full Research Report on Amedisys, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/56b5_AMED

--

The Ensign Group, Inc. Research Report  

On December 16, 2013, The Ensign Group, Inc. (Ensign Group) announced that its
Board of Directors has declared a quarterly cash dividend of $0.07 per share
of the Company's common stock. According to the Company, the dividend is
payable on or before January 31, 2014, to shareholders of record as of
December 31, 2013. "The increased dividend is consistent with our improved
earnings, strong cash flow and additional growth in 2013," said Christopher
Christensen, Ensign's President and CEO. "This is the eleventh consecutive
year Ensign has increased its dividend, which reflects our continued
confidence in Ensign's operating model and in our ability to return long-term
value to our shareholders." The Full Research Report on The Ensign Group, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cc60_ENSG

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement